USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Anglo-American antibiotics developer Summit Therapeutics opened up more than 10% on Thursday following news that it is to receive further US government funding for its C difficile infection (CDI) drug candidate. 16 August 2018
Accelerator Life Science Partners and the University of Texas MD Anderson Cancer Center have announced the launch of Magnolia Neurosciences, a drug discovery and development company focused on creating a novel class of neurological therapies. 13 August 2018
A Chinese oncology company that is developing biosimilars and innovative drugs, has announced the completion of a Series B financing round, raising $102 million in capital. 9 August 2018
Digital medicine company Akili Interactive Labs, an independent affiliate of the biotech company PureTech Health, has announced an additional $13 million worth of investment in its ongoing Series C funding campaign, which now totals $68 million. 9 August 2018
Samumed, a US biopharmaceutical startup, has concluded its Series A fundraising campaign having raised $438 million based on a valuation of $12 billion. 6 August 2018
With the aim of expanding their horizon in oncology with a new set of T cell receptor targets, the USA’s Regeneron Pharmaceutical has struck a deal with fellow biotech bluebird bio. 6 August 2018
Japan’s largest drugmaker Takeda Pharmaceutical has teamed up with Japan-based alternative asset management firm, Whiz Partners to create a joint investment fund, aimed at promoting a drug discovery ecosystem in Japan. 3 August 2018
UK-based antiviral drug discovery and development company ReViral today announced the successful completion of a $55 million Series B financing. 1 August 2018
One year after raising $800 million in a follow-on public offering, BeiGene has announced it will list on the Hong Kong stock exchange with an initial public offering (IPO) expected to bring in an even greater sum for the Beijing-based firm. 27 July 2018
In the 1980s, technologies such as DNA editing started to mature, creating a range of sophisticated and transformative therapeutic techniques - and a race to secure funding, technologies and expertise. 27 July 2018
Today San Francisco, USA-based biotech start-up Alector announced the closing of a $133 million Series E financing and for the first time revealed its first three programs focused on Alzheimer’s disease and frontotemporal dementia (FTD). 25 July 2018
Sanofi Ventures, the investment arm of French pharma major Sanofi has entered into a $17 million deal with New York-based Click Therapeutics. 23 July 2018
Chinese biopharma start-up Ascentage Pharma has announced the successful completion of approximately $150 million in a Series C financing, bringing the total capital raised since the Company's launch to around $240 million. 17 July 2018
East Coast, USA-based I-O startup Compass Therapeutics has finished raising $132 million to take its lead candidate into the clinic and identify two more clinical candidates. 13 July 2018
Medicinal cannabis has been a hot topic in the USA and the UK in recent weeks, and an Australian company joined the party on Thursday with some news of its own. 5 July 2018
Dutch biotech company VarmX, which focuses on the development of therapies in the field of hemostasis and thrombosis, today announced the closing of a Series A financing round of 7.5 million euros ($8.8 million). 2 July 2018
I-Mab Biopharma, a Chinese biotech company focusing on innovative biologics in therapeutic areas of immuno-oncology and immuno-inflammation, has completed a Series C financing for $220 million, representing one of the largest amounts ever raised in Series C by an innovative biotech company in China. 2 July 2018
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news